HOME >> BIOLOGY >> NEWS
Study detailing safety and efficacy of exisulind in treating recurrent prostate cancer

HORSHAM, PA (August 9, 2001): Cell Pathways, Inc. (Nasdaq: CLPA) today announced publication of the detailed results of a double-blind, placebo-controlled clinical study of exisulind in the treatment of recurrent prostate cancer following radical prostatectomy in the September issue of The Journal of Urology. The results of the Phase II/III study, involving 96 patients at multiple centers throughout the United States, demonstrated that exisulind inhibited the rise in PSA (prostate specific antigen) levels in treated men overall and significantly prolonged PSA doubling time in high-risk patients compared with placebo. The study was supported by a grant from Cell Pathways, and the results were initially reported by the principal investigator at the 95th annual meeting of the American Urological Association in May 2000.

These results suggest that exisulind may delay disease progression in men with recurrent prostate cancer and thus prolong the time period between initial post-surgical PSA rise and the need for androgen deprivation therapies, said Erik T. Goluboff, MD, assistant professor of urology at Columbia University College of Physicians & Surgeons and director of urology at the Allen Pavilion of NewYork-Presbyterian Hospital, principal investigator of the study. Hormonal therapy produces high response rates in metastatic prostate cancer, but patients develop resistance over time. The side effects of hormonal treatment can significantly impact the patients quality of life. New treatment options that might delay the need for such side effect prone therapies could provide great benefit in the management of prostate cancer.

The primary efficacy measurement for the one-year, single-agent study was the difference in the change in PSA levels from baseline between the placebo-treated and exisulind-treated groups. The clinical effect of exisulind therapy was initially observed two to three months after commencing treatment, and continued throughout the st
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
9-Aug-2001


Page: 1 2 3 4

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: